论文部分内容阅读
目的 :检验利培酮在首发精神分裂症治疗中锥体外系症状 (EPS)的发生率。 方法 :以锥体外系症状评定量表对 46例首次发作、从未应用抗精神病药物治疗的精神分裂症患者 ,在应用利培酮治疗的前、中、后进行检查。 结果 :有 6例 (13.0 % )患者在治疗前就存在明显的 EPS,但在利培酮治疗后都未出现 EPS。在利培酮最高治疗量时 (4～ 6 mg/ d) ,13例 (2 8.3% )出现轻度静坐不能或帕金森征 ,减少剂量后均减轻或消失。在接受利培酮≤ 3m g/ d治疗的患者中 ,均未出现有临床意义的EPS。 结论 :这些结果对指导精神分裂症的早期及长期治疗有一定的临床意义
PURPOSE: To test the incidence of extrapyramidal symptoms (EPS) in risperidone-treated first-episode schizophrenia. METHODS: Forty-six patients with schizophrenia, who were first attacked and never treated with antipsychotics, were examined before, during, and after treatment with risperidone using the Extrapyramidal Symptom Rating Scale. RESULTS: Six patients (13.0%) had significant EPS prior to treatment, but no EPS occurred after risperidone treatment. At the highest doses of risperidone (4 to 6 mg / d), 13 patients (2 8.3%) developed mild or no Parkinson’s symptoms and reduced or disappeared after dose reduction. In patients receiving risperidone ≤ 3 m g / d, no clinically significant EPS occurred. Conclusions: These results have some clinical implications for the early and long-term treatment of schizophrenia